DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma: A subgroup analysis in patients with high-risk cytogenetic features

The DREAMM-8 study (NCT04484623) evaluated belantamab mafodotin plus pomalidomide and dexamethasone (BPd) versus pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma patients, specifically a subgroup with high-risk cytogenetic abnormalities (HRCAs). BPd demonstrated clinically meaningful improvements in progression-free survival (median 21.1 vs 9.2 months), overall response rate (76% vs 65%), and deep responses in this population, supporting its potential as a standard-of-care regimen.